EGFR and non-small cell lung carcinoma: Moreover, LSM was consistently effective in identifying the subset of patients with advanced NSCLC who could benefit from Chemo+ICIs, not only as subsequent-line therapy of EGFR-mutant NSCLCs after developing disease progression with EGFR-TKI, but also as first-line treatment of NSCLCs without actionable mutations.